At its investor meeting on 30 September, Roche Holding AG highlighted its obesity candidate CT-388 as one of the programs it intended to throw extra resources behind to speed its path to market (Also see "Roche Aims To ‘Raise The Bar’ With New Wave Of Blockbusters" - Scrip, 30 September, 2024.). Early data on the GIP/GLP-1 agonist, which Roche obtained via its acquisition of Carmot Therapeutics Inc. last year, suggest it could cause a highly respectable degree of weight loss. (Also see "Roche’s New Obesity Play Shows Early Promise" - Scrip, 16 May, 2024.)
Roche’s Plan To Muscle In On Obesity
The Swiss group’s head of cardiovascular, renal and metabolism aims to speed its incretins to market, and tackle the plateauing of weight loss and muscle wastage through combinations.
